Abstracts tagged "B-Cell Targets"

Abstract Number: 111 • 2023 Pediatric Rheumatology Symposium
Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center
Omar Mostafa, Sharon Bout-Tabaku, Buthaina Al-Adba, Ahmad Kaddourah, Abubakr Imam, Ibrahim Shatat and Mohammed Yousuf Karim, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Hypogammaglobulinemia is an under-recognized complication of B-cell targeted therapies (BCTT) in both autoimmune diseases (AID) and malignancy. Hypogammaglobulinemia may be transient or persistent, and…
Abstract Number: L07 • ACR Convergence 2022
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Di Wu¹, Jing Li¹, Dong Xu¹, Li Wang¹, Jianmin Fang², Dan Ross³ and Fengchun Zhang⁴, ¹Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, ²Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, ³RemeGen Co., San Diego, CA, ⁴Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China
Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
Abstract Number: L16 • ACR Convergence 2022
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Benjamin Terrier¹, Laura Richert², Grégory Pugnet³, Olivier Aumaitre⁴, Olivier Moranne⁵, Elisabeth Diot⁶, Alexandre Karras⁷, Fabrice Bonnet⁸, Claire De Moreuil⁹, Eric Hachulla¹⁰, Thomas Le Gallou¹¹, Céline Lebas¹⁰, Francois Maurier¹², Cédric Rafat⁷, Maxime Samson¹³, Jean-Francois Augusto¹⁴, Grégoire Couvrat-Devergne¹⁵, Cécile Janssen¹⁶, Thierry Martin¹⁷, Thomas Quemeneur¹⁸, Pierre-Louis Caron¹⁹, Cécile-Audrey Durel²⁰, Khalil El Karoui⁷, Aurélie Grados²¹, Mathieu Puyade²², Virginie Rieu⁴, Yurdagul Uzunhan²³, Jean-Francois Viallard⁸, Xavier Puéchal⁷, Loic Guillevin⁷, Noémie Huchet⁸, Hendy Abdoul⁷, Carine Bellera⁸, Frédéric Batteux⁷ and Odile Launay⁷, ¹Cochin Hospital, Paris, France, ²EUCLID, Bordeaux, France, ³CHU, Toulouse, France, ⁴CHU, Clermont-Ferrand, France, ⁵CHU, Nimes, France, ⁶CHU, Tours, France, ⁷CHU, Paris, France, ⁸CHU, Bordeaux, France, ⁹CHU, Brest, France, ¹⁰CHU, Lille, France, ¹¹CHU, Rennes, France, ¹²CH, Metz, France, ¹³CHU, Dijon, France, ¹⁴CHU, Angers, France, ¹⁵CH, La Roche sur Yon, France, ¹⁶CH, Annecy, France, ¹⁷CHU, Strasbourg, France, ¹⁸CH, Valenciennes, France, ¹⁹CHU, Grenoble, France, ²⁰CHU, Lyon, France, ²¹CH, Niot, France, ²²CHU, Poitiers, France, ²³CHU, Bobigny, France
Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
Abstract Number: 0527 • ACR Convergence 2022
Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials
Florence Delestre¹, Pierre Charles², Loïc Guillevin³, Raphaël Porcher⁴ and Benjamin Terrier³, ¹cochin Hospital, Paris, France, ²Institut Mutualiste Montsouris, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…
Abstract Number: 1632 • ACR Convergence 2022
Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B
Sherri Longobardi¹, Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Constantin Georgescu¹, Christina Lawrence¹, Astrid Rasmussen¹, Lida Radfar², R. Hal Scofield², Robert C. Axtell¹, Gabriel Pardo¹, Jonathan Wren¹, Kristi A Koelsch¹, Joel Guthridge¹, Judith James¹, Christopher Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Classification of Sjögren's disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD…
Abstract Number: 0624 • ACR Convergence 2022
CD20+ T Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Suggest a Role for Trogocytosis in Disease Pathogenesis and Activity
Maria De Santis¹, Natasa Isailovic², Giacomo Maria Guidelli³, Daniela Renna⁴, Arianna Sonaglia³, Nicoletta Luciano³, Marta Caprioli⁵, Angela Ceribelli¹, Francesca Motta⁶, Matteo Vecellio¹, Enrico Brunetta³ and Carlo Selmi¹, ¹Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Rozzano (MI), Italy, Rozzano, Italy, ³IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ⁴IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Milano, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy
Background/Purpose: Approximately 1-2% of peripheral blood T cells express CD20, a marker of the B lineage, in both healthy individuals and patients with rheumatoid arthritis…
Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Brian J. Mog¹, Elana R. Shaw¹, Michael S. Hwang¹, Alexander H. Pearlman¹, Sarah R. DiNapoli¹, Suman Paul¹, Chetan Bettegowda¹, Nickolas Papadopoulos¹, Sandra B. Gabelli¹, Michelle Petri², Antony Rosen¹, Shibin Zhou¹, Kenneth W. Kinzler¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
Abstract Number: 0644 • ACR Convergence 2022
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
Jennifer Barnas¹, Diana Alzamareh², Neha Nandedkar-Kulkarni², Jennifer Albrecht², Nida Meednu², Cameron Baker², Andrew McDavid¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells (PC) play a…
Abstract Number: 1869 • ACR Convergence 2022
Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
Christopher Costin¹, Gabrielle Morgan², Amer Khojah³ and Lauren Pachman⁴, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: B Cell Activating Factor (BAFF) is a cytokine that drives B Cell proliferation and maturation. B Cells remain an important factor in JDM immune…
Abstract Number: 0720 • ACR Convergence 2022
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
Jun Won Park¹, Jeffrey Curtis², Min Jung Kim³, You-Jung Ha⁴, Yun Jong Lee⁴ and Eun Bong Lee¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ⁴Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: Although previous studies suggested that primary prophylaxis for pneumocystis pneumonia (PJP) during rituximab treatment could be beneficial, it is uncertain whether this strategy should…
Abstract Number: 1872 • ACR Convergence 2022
Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
Fahidah Alenzi¹, Shirish Sangle² and Sanna Giovanni², ¹Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: Idiopathic inflammatory myositis (IIM) includes a spectrum of a rare autoimmune disease characterized by proximal muscle weakness, variable skin manifestation and extra muscular manifestations.…
Abstract Number: 0754 • ACR Convergence 2022
Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
Ana-Luisa Stefanski¹, Hector Rincon-Arevalo¹, Eva Schrezenmeier², Franziska Szelinski¹, Jacob Ritter³, Yidan Chen¹, Christian Meisel⁴, Hubert Schrezenmeier⁵, Andreia C. Lino⁶ and Thomas Dörner¹, ¹Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin; DRFZ Berlin; Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Department of Medical Immunology, Charité University Medicine and Labor Berlin-Charité Vivantes, Berlin, Germany, ⁵Institute of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen and University Hospital Ulm, Ulm, Germany, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: Durable vaccine-mediated immunity relies on the generation of long-lived plasma cells and memory B cells (MBCs), differentiating upon germinal center (GC) reactions. SARS-CoV-2 mRNA…
Abstract Number: 2037 • ACR Convergence 2022
Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype
Lucia Martin-Gutierrez¹, Hannah Peckham², Anna Radziszewska², Junjie Peng², Oluwatomisin Nettey², Elizabeth Jury³ and Coziana Ciurtin⁴, ¹Centre for Rheumatology Research, Department of Medicine,University College London, London, ²Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, ³University College London, London, United Kingdom, ⁴Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune rheumatic disease characterised by dryness resulting from chronic lymphocytic infiltration of the exocrine glands and extra glandular manifestations…
Abstract Number: 0977 • ACR Convergence 2022
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
Jason S Knight¹, Winn Walter Chatham², Christine Henning³, Julia H N Harris⁴, Andre Van Maurik⁵, Roger A Levy⁶ and David Pisetsky⁷, ¹University of Michigan, Division of Rheumatology, Ann Arbor, MI, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL, ³GlaxoSmithKline, Global Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷Duke University Medical Center, Durham, NC
Background/Purpose: Serological and cellular biomarkers are used in clinical practice to guide the management of SLE. Increased levels of anti-dsDNA and decreased levels of complement…
Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa¹, Jeffrey Zhang-Sun¹, Paul Christos² and Kyriakos Kirou¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine/New York-Presbyterian, New York, NY
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…